cell and gene therapy world

22-25 JANUARY 2019 // HYATT REGENCY, MIAMI

translational academy

Phacilitate and Cell and Gene Therapy Insights teamed up to further support collaboration between academic and industry pioneers.

 

The Translation Academy will highlight promising innovation and support its path to commercial success, focusing on the following themes:

Financing

Manufacturing

Regulatory

Reimbursement

Partners

bioinsights crm fresenius

 

 

Agenda

DAY 1 - TUESDAY, JANUARY 23
11:00 - 11:30

Morning coffee

Beginning with the end in mind
Dr Sven Kili, Vice President & Head of Cell & Gene Therapy Development, Rare Disease Unit, GlaxoSmithKline 
  Interviewed by: Elisa Manzotti, CEO & Founder, BioInsights

13:00 - 14:00

 

Lunch

Reimbursement Panel Discussion and Case Study - Reimbursement considerations for cell and gene therapies.             

Chair: Dr Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM) 
Speaker:  Dr Panos Kefalas, Head of Health Economics & Market Access, Cell and Gene Therapy Catapult
Panellists: 
Dr Sven Kili, Vice President & Head of Cell & Gene Therapy Development, Rare Disease Unit, GlaxoSmithKline
Chris Mason, MD, PhD, CSO, AvroBio

17:45 - 18:00

Evening reception

Translational Pioneer Award Winner Q&A- BioInsights

18:00 - 18:45   MaSTherCell global announcement 

 

DAY 2 - WEDNESDAY, JANUARY 24

07:30 - 08:30

Breakfast/Registration

Financing Panel Discussion and Case Study

Chair: Dr Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM)  
Speaker: Dr Reni Benjamin, Senior Biotechnology Analyst, Raymond James & Associates, Inc 
Panellists:
Geoff MacKay, CEO, AvroBio
 Greg Bonfiglio, Founder & Managing Partner, Proteus, LLC 
 Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult    

10:45 - 11:15

Morning coffee

Utilizing Academia for translation of cell and gene therapies to the clinic

Speaker: Dr David DiGiusto, Executive Director, Stanford University School of Medicine

13:00 - 14:00

Lunch

Cell and Gene Therapy Manufacturing Considerations.   

 Chair: Dr Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM) 
 Speaker:  Dr Aaron Dulgar-Tulloch, Director BridGE@CCRM, GE Healthcare
Panellists:
Dave Smith. Vice President Global Business Development, Lonza 
 Claudia Zylberberg, PhD, CEO, Akron Biotech

15:30 - 16:00

Afternoon tea

Troubleshooting academia-industry tech transfer

Dr Shashi Murthy, Professor, Northeastern University  
    Interviewed by: Elisa Manzotti, CEO & Founder, BioInsights

 

DAY 3 - THURSDAY, JANUARY 25

07:30 - 08:30

Breakfast/Registration

Regulatory Panel Discussion and Case Study

Chair: Dr Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM)   
Speaker: Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine (ARM) 
  Panellists:
Kunihiko Suzuki, Vice Chairman, FIRM   
Lee Buckler, President & CEO, RepliCel Life Sciences, Inc   

10:45 - 11:15

Morning coffee

Interview: Regulatory insights for translational R&D
Abla A. Creasey, PhD, Senior Director, Strategic Clinical, Regulatory & Infrastructure, California Institute for Regenerative Medicine (CIRM)     

Interviewed by: Elisa Manzotti, CEO & Founder, BioInsights

13:00 - 14:00

Lunch

Cell & Gene Therapy World in summary: Highlights and trends from this year’s event

Co-Moderators:  Brian Hampson, Vice President, Global Manufacturing Sciences & Technology, Hitachi Chemical Advanced Therapeutics
Thomas Heathman, PhD, Business Leader, Technology Development, Manufacturing  Development & GTP Services, Hitachi Chemical Advanced Therapeutics
David Smith, PhD, Biomedical Engineer, Innovation & Engineering, Hitachi Chemical Advanced Therapeutics

 

Translational Pioneer Award

Following the inaugural award presented in 2017 to Carl H.June, M.D., Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania, Phacilitate in partnership with Cell & Gene Therapy Insights are delighted to announce the call for nominations for the 2018 Cell & Gene Therapy Translational Pioneer Award.

This award has been designed to recognize the exceptional contribution made by an individual scientist to the translation of cell and gene therapies into the clinic, and will be presented live at Cell & Gene Therapy World. Our expert panel of judges includes:

Olivier Danos, Chief Science Officer, REGENXBIO Inc.

Joanne Kurtzberg, Director, Carolinas Cord Blood Bank, Duke University

Chris Mason, Chief Science Officer, AVROBIO

 

Shortlisted nominees will be announced in mid-December 2017, with our judging panel deciding on the winner a couple of weeks later. The winner will benefit from a free conference pass and an exclusive interview in Cell & Gene Therapy Insights!

  • "The event reflected the fantastic growing enthusiasm around cell and gene therapy, including small and large companies, investors and regulators. It was great to see everyone so engaged and so positive. The event really gives you the “pulse” of what is happening right now in cell and gene therapy."
    Anne-Virginie Eggimann,
  • “Great program, great people, great venue.”
    Klaus Kühlcke
    Managing Director, EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.”
    Nathalie Clement
    Associate Director, Powell Gene Therapy Center, University of Florida
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • "It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives."
    Kurt Gielen
    Acquisition & Business Development Manager, BioMedical Materials, Chemelot Campus B.V.
  • “Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.”
    Steven Goodman
    Director, Strategy and Engagement, GSK